Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 14/20 | 0.57 |
| ▸ | TUBB4A | P04350 | 11/20 | 0.57 |
| ▸ | TUBB | P07437 | 11/20 | 0.57 |
| ▸ | TUBA3C | P0DPH7 | 11/20 | 0.57 |
| ▸ | TUBA1B | P68363 | 11/20 | 0.57 |
| ▸ | TUBA4A | P68366 | 11/20 | 0.57 |
| ▸ | TUBB4B | P68371 | 11/20 | 0.57 |
| ▸ | TUBB3 | Q13509 | 11/20 | 0.57 |
| ▸ | TUBB2A | Q13885 | 11/20 | 0.57 |
| ▸ | TUBB8 | Q3ZCM7 | 11/20 | 0.57 |
| ▸ | TUBA3E | Q6PEY2 | 11/20 | 0.57 |
| ▸ | TUBA1A | Q71U36 | 11/20 | 0.57 |
| ▸ | TUBA1C | Q9BQE3 | 11/20 | 0.57 |
| ▸ | TUBB6 | Q9BUF5 | 11/20 | 0.57 |
| ▸ | TUBB2B | Q9BVA1 | 11/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7126370 | 0.93 | TUBB1 (0.57) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6859909 | 0.91 | TUBB4A (0.46) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL7121019 | 0.90 | TUBB1 (0.46) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6860006 | 0.90 | TUBB1 (0.64) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6009342 | 0.90 | TUBB1 (0.67) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL7125616 | 0.89 | TUBB4A (0.44) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6860039 | 0.88 | TUBB1 (0.56) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6853129 | 0.87 | TUBB1 (0.49) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL7129321 | 0.86 | TUBB4A (0.48) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6321031 | 0.86 | TUBB4A (0.46) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453783-A1 | SUBSTITUTED ARYL-CYCLOALKANES, AND USE THEREOF AS ANTICANCER AGENTS | Aventis Pharma S.A. (FR) | 2004-09-08 | — | — | EP | disclosed |
| US-20030149072-A1 | Substituted arylcycloalkanes, compositions containing them and use thereof | AVENTIS PHARMA S.A. (FR) | 2003-08-07 | — | — | US | disclosed |
| WO-2003048096-A1 | SUBSTITUTED ARYL-CYCLOALKANES, AND USE THEREOF AS ANTICANCER AGENTS | AVENTIS PHARMA S.A. (FR) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149072-A1 | Substituted arylcycloalkanes, compositions containing them and use thereof | ABL1, MCL1, AHR | TUBB1 1801/4885TUBB4A 1571/4885TUBB 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.